Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Indianapolis, Indiana
- Most recent report
- 10-Q, filed Aug 5, 2026
- Incorporated
- Indiana
- Filings on record
- 1,008+ filings
- On EDGAR
- CIK 59478
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 19
News 8 of 45
Prospectuses and Registrations 8 of 23
- 25-NSE Notice that a security was delisted Jun 2, 2026
- 424B2 Prospectus supplement for an offering May 8, 2026
- FWP Free writing prospectus May 6, 2026
- 424B2 Prospectus supplement for an offering May 6, 2026
- 424B2 Prospectus supplement for an offering Aug 19, 2025
- FWP Free writing prospectus Aug 18, 2025
- 424B2 Prospectus supplement for an offering Aug 18, 2025
- 25-NSE Notice that a security was delisted Jun 2, 2025
Proxies 8 of 32
- PX14A6G Shareholder's own proxy material Apr 29, 2026
- DEFA14A Extra proxy material Mar 20, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 20, 2026
- PRE 14A Preliminary proxy statement Mar 6, 2026
- PX14A6G Shareholder's own proxy material Mar 31, 2025
- DEFA14A Extra proxy material Mar 21, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 21, 2025
- PRE 14A Preliminary proxy statement Mar 7, 2025
Ownership 8 of 828
- 3/A Insider reported their initial holding, amended Sep 4, 2026
- 4 Insider reported a trade Sep 4, 2026
- 4 Insider reported a trade Sep 4, 2026
- 4 Insider reported a trade Aug 18, 2026
- 4 Insider reported a trade Aug 18, 2026
- 4 Insider reported a trade Aug 18, 2026
- 4 Insider reported a trade Aug 18, 2026
- 4 Insider reported a trade Aug 18, 2026
Other 8 of 61
What to read: Jun 2026 10-Q
SECSift found 2 of 11 sections worth reading, with 2 positive, 5 notable, and 7 negative flags.
Financial Statements (Item 1)
Financials show 48% revenue growth, heavy acquisition spend, and multiple litigation updates.Negative- Emgality patent: Federal Circuit reversed in April 2026; we recognized a charge and now seek rehearing en banc.
- Cipla filed ANDA for generic Verzenio in April 2026; Lilly filed suit.
- Multiple generic companies filed ANDAs for Mounjaro/Zepbound in July 2026.
- Michigan Supreme Court reversed appeals court in insulin pricing case, reopening investigation.
- Supreme Court denied review in AMP pricing litigation; charge stands.
Management's Discussion (Item 2)
Dense with material facts: big revenue growth, heavy M&A/debt, pipeline milestones, pricing risks.PositiveNotable- Acquired IPR&D charges surged from $154M to $2,776M in Q2 2026, from Orna and Ajax buys.
- Asset impairment, restructuring charges of $703M in Q2 2026 (vs $0) from acquisition costs.
- Paid $13.3B for H1 2026 business development: Centessa, Kelonia, Orna, Ventyx, Ajax.
- Total debt increased to $54.9B from $42.5B at year-end, after $9.0B debt issuance in May 2026.
What changed: Jun 2026 vs. Mar 2026
About 16% of LLY's Jun 2026 10-Q is new information. 44 paragraphs were added, 80 changed, and 42 removed. Below are the most important lines SECSift identified.
New
- Paid $2.0B for infectious disease portfolio in July 2026; pending $2.8B for AtaiBeckley. Item 2
- Issued $9.0B in long-term debt in May 2026. Item 2
- Issued $9B long-term debt in May 2026 to fund acquisitions and repay commercial paper. Item 1
- Submitted orforglipron for type 2 diabetes in the U.S., the EU, and Japan. Item 2
Everything here comes from ELI LILLY & Co's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Aug 19, 2026, from the 10-Q for Jun 2026.